JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
Scope & Guideline
Connecting researchers and practitioners in cardiovascular pharmacology.
Introduction
Aims and Scopes
- Cardiovascular Drug Development:
The journal publishes studies investigating new pharmacological agents and their mechanisms of action in treating cardiovascular diseases, highlighting advancements in drug development. - Clinical Pharmacology and Therapeutics:
Research on the clinical application of cardiovascular drugs, including efficacy, safety, and pharmacokinetics, is central to the journal's scope. - Mechanisms of Cardiovascular Disease:
The journal explores the underlying biological mechanisms of cardiovascular diseases, providing insights into how various drugs can modify these pathways. - Personalized Medicine and Pharmacogenetics:
A focus on tailoring cardiovascular treatments based on genetic and phenotypic patient characteristics to optimize therapeutic outcomes. - Emerging Therapies and Innovations:
The publication highlights novel therapeutic approaches, including the use of biologics, gene therapy, and advanced drug delivery systems in cardiovascular care. - Interventional Cardiology:
Research on pharmacologic strategies during interventional procedures such as angioplasty and stenting, particularly concerning antiplatelet therapy and anticoagulation. - Cardiovascular Safety and Risk Management:
Studies addressing the safety profiles of cardiovascular drugs, including adverse effects, drug interactions, and risk factors associated with their use.
Trending and Emerging
- Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors:
Research on SGLT2 inhibitors has surged, emphasizing their role in heart failure management and cardiovascular protection beyond glucose control. - Antithrombotic Strategies and Dual Antiplatelet Therapy:
There is a growing emphasis on optimizing antithrombotic therapies, including novel approaches to dual antiplatelet therapy and their implications for various patient populations. - Biologics and Novel Therapeutics:
The journal increasingly features studies on biologics and new therapeutic modalities, reflecting a shift towards innovative treatment options in cardiovascular diseases. - Cardiovascular Outcomes in Diabetes Management:
Research on the cardiovascular implications of diabetes medications, particularly their effects on heart failure and other cardiovascular outcomes, is gaining prominence. - Regenerative Medicine and Stem Cell Therapy:
Emerging studies on the use of stem cells and regenerative medicine approaches to treat cardiovascular conditions are becoming a significant focus. - Pharmacogenomics in Cardiovascular Treatment:
The integration of pharmacogenomics into cardiovascular treatment strategies is increasingly prevalent, highlighting the importance of personalized medicine. - Impact of Inflammation on Cardiovascular Health:
Research exploring the role of inflammation in cardiovascular diseases and the potential therapeutic targets is trending, reflecting a growing understanding of pathophysiological mechanisms.
Declining or Waning
- Traditional Pharmacotherapies:
Research on established therapies, such as older anticoagulants and antiplatelet agents, appears to be waning as newer, more effective alternatives gain traction and clinical relevance. - Single-Agent Efficacy Studies:
There is a noticeable decline in studies focusing solely on the efficacy of single-agent therapies, as the field moves towards combination therapies and multi-target approaches. - Basic Science Studies Without Clinical Relevance:
Basic research studies that do not translate into clinical applications or implications are becoming less common, as the journal emphasizes translational research that impacts patient care. - Longitudinal Studies on Drug Safety:
Fewer longitudinal studies focusing on the long-term safety of cardiovascular drugs are being published, possibly due to a shift towards larger, multi-center trials that provide more comprehensive data.
Similar Journals
Netherlands Heart Journal
Elevating Standards in Cardiology with Cutting-Edge FindingsNetherlands Heart Journal is a premier academic publication dedicated to advancing knowledge in the field of cardiology and cardiovascular medicine. Published by BOHN STAFLEU VAN LOGHUM BV, this journal has established itself as a critical platform for researchers, professionals, and students seeking to explore groundbreaking findings and innovative practices in cardiovascular health. With an ISSN of 1568-5888 and E-ISSN 1876-6250, the journal boasts a respectable Q2 ranking in the Cardiology and Cardiovascular Medicine category, placing it in the top half of its field according to the 2023 quartiles. The Scopus ranking places it 130th out of 387 in the relevant category, indicating a commendable percentile rank of 66th, which attests to its influence and quality of published research. Spanning from 2005 to 2024, the journal endeavors to include a diverse array of topics, encompassing clinical practice, technological innovations, and public health considerations related to cardiovascular diseases. Researchers and practitioners are encouraged to engage with the journal's robust content, contributing to and benefiting from the collaborative effort to enhance cardiovascular health worldwide.
CARDIOVASCULAR RESEARCH
Advancing the frontiers of cardiovascular science.CARDIOVASCULAR RESEARCH, published by Oxford University Press, is a premier academic journal dedicated to the evolving field of cardiology and cardiovascular medicine. With a remarkable impact factor reflecting its significant contribution to the scientific community, this journal maintains a Q1 ranking in both Cardiology and Physiology categories, demonstrating its commitment to publishing high-quality research that influences clinical practices and healthcare outcomes. Established in 1967, the journal has consistently provided a platform for innovative studies and reviews, aiming to advance our understanding of cardiovascular physiology and pathology. Researchers, professionals, and students will find published articles crucial for their work, as the journal covers a broad spectrum of topics including molecular biology, genetics, and clinical studies. While currently not offering open access options, CARDIOVASCULAR RESEARCH remains accessible through institutional and individual subscriptions, ensuring that the latest findings are available to those in the cardiovascular science community.
CIRCULATION
Shaping the Future of Cardiology Through Rigorous Research.CIRCULATION is a premier journal in the field of cardiology and cardiovascular medicine, published by Lippincott Williams & Wilkins. With a distinguished history dating back to 1950, the journal has consistently been at the forefront of critical research, showcasing significant advancements and discoveries in cardiovascular health. It holds a remarkable Q1 ranking in both the fields of Cardiology and Physiology (medical) according to the 2023 category quartiles, demonstrating its influential role among the top publications in these disciplines. With an impressive Scopus ranking, placed 3rd out of 387 in Cardiology and 2nd out of 113 in Physiology, CIRCULATION is essential reading for researchers, practitioners, and students passionate about advancing their understanding of heart health and related medical sciences. Although the journal is not open access, it continues to foster scholarly exchange and innovation in cardiovascular research, making it an indispensable resource for quality insights and groundbreaking studies.
Cardiology in Review
Bridging research and practice in cardiology.Cardiology in Review, published by Lippincott Williams & Wilkins, is a prominent journal focused on advancing the field of cardiology and cardiovascular medicine. With a history of publication spanning from 1995 to 2024, the journal serves as an essential resource for researchers, healthcare professionals, and students alike, offering in-depth reviews and analyses on the latest developments, clinical practices, and research findings in cardiology. Despite being a traditional print journal, it maintains a commendable Q2 ranking in both cardiology and miscellaneous medicine categories as of 2023, reflecting its influence and rigor in the academic community, with a Scopus rank of #132 out of 387 in its field, placing it in the 66th percentile. The journal aims to bridge the gap between clinical practice and emerging research, promoting a deeper understanding and integration of innovative strategies in cardiovascular care. With its commitment to high-quality scholarship, Cardiology in Review remains a vital conduit for knowledge and dialogue within the evolving landscape of cardiovascular health.
Journal of the Practice of Cardiovascular Sciences
Advancing Cardiovascular Knowledge for a Healthier TomorrowJournal of the Practice of Cardiovascular Sciences, published by Wolters Kluwer Medknow Publications, is an esteemed Open Access journal dedicated to advancing knowledge in the field of cardiovascular health. With its ISSN 2395-5414 and E-ISSN 2454-2830, the journal serves as a vital platform for researchers, healthcare professionals, and students to disseminate and access high-quality studies, innovations, and practical applications related to cardiovascular sciences. Established in 2015 as an Open Access journal, it promotes widespread sharing of insights to enhance cardiovascular practices and address contemporary challenges in the field. As part of a reputable publishing group, the journal is poised for growth and impact, contributing significantly to the ongoing dialogue in cardiovascular research and clinical practice.
Clinica e Investigacion en Arteriosclerosis
Transforming insights into impactful clinical practices.Clinica e Investigacion en Arteriosclerosis is a premier academic journal dedicated to the field of cardiology and cardiovascular medicine, published by ELSEVIER. With its ISSN 0214-9168 and E-ISSN 1578-1879, the journal aims to disseminate high-quality research and innovations in the understanding and treatment of arterial diseases, contributing significantly to both clinical practices and pharmacological advancements. Established in 2007 and continuing into 2024, the journal has garnered recognition with a notable Q3 categorization in both Cardiology and Cardiovascular Medicine and Pharmacology (medical) for 2023, reflecting its impact in the academic community. Researchers and healthcare professionals utilizing this journal will find a diverse range of articles exploring novel therapeutic strategies and epidemiological data, making it an essential resource for advancing knowledge and practice in cardiovascular health. While it does not operate as an open-access journal, the findings published in Clinica e Investigacion en Arteriosclerosis are pivotal for understanding current trends and future directions in cardiovascular research.
Cardiovascular Innovations and Applications
Advancing cardiovascular knowledge for a healthier tomorrow.Cardiovascular Innovations and Applications is a premier open-access journal dedicated to advancing knowledge in the field of cardiovascular medicine. Published by COMPUSCRIPT since 2016, this journal provides a platform for the dissemination of innovative research and applications that address crucial topics in cardiology, aiming to bridge the gap between clinical practice and cutting-edge research. With an ISSN of 2009-8618 and an E-ISSN of 2009-8782, it operates on a global scale, facilitating access to high-quality content without financial barriers. The journal is positioned within the Medicine - Cardiology and Cardiovascular Medicine category, and its current Scopus rank of #321/387 reflects its potential for growth and influence in the academic community, being in the 17th percentile. Researchers, healthcare professionals, and students will find Cardiovascular Innovations and Applications an invaluable resource in their quest for the latest findings and advancements in cardiovascular health and treatment methodologies.
VASCULAR PHARMACOLOGY
Transforming insights into therapies for vascular diseases.Vascular Pharmacology, published by Elsevier Science Inc, is a leading journal in the fields of pharmacology and molecular medicine, dedicated to advancing our understanding of vascular biology and therapeutic interventions. With an impressive impact factor reflecting its significant contribution to the scientific community, this journal seeks to publish ground-breaking research that elucidates the molecular mechanisms underlying vascular function and disease, as well as the pharmacological impact of new therapeutic agents. The journal operates under a dual access model, allowing for both subscription and open access options, ensuring that vital research is accessible to a wide audience. As of 2023, it holds a prestigious position in the Q1 category for pharmacology and ranks well in molecular medicine and physiology, reflecting its high quality and relevance. Whether you are a researcher, clinician, or student, Vascular Pharmacology serves as an essential resource to stay at the forefront of cardiovascular pharmacotherapy and vascular biology.
Journal of Pharmacological Sciences
Connecting researchers to drive pharmaceutical breakthroughs.Journal of Pharmacological Sciences is a leading peer-reviewed academic journal dedicated to the field of pharmacology, published by the Japanese Pharmacological Society. Since its inception, this journal has offered an essential platform for the dissemination of high-quality research, contributing significantly to advancements in molecular medicine and pharmacology. With an impact factor that places it in the prestigious Q2 quartile for both categories, the journal has established itself as a credible source of innovative findings and methodologies since its transition to Open Access in 2015. This accessibility enables a broader audience, including researchers, healthcare professionals, and students, to engage with valuable insights and discussions pertinent to drug development, pharmacodynamics, and therapeutic strategies. Based in Kyoto, Japan, the journal serves as a vital resource for the global pharmacological community, encouraging collaboration and research that leads to improved health outcomes. For more information, submissions, and access to the latest research, visit the journal’s website.
PROGRESS IN CARDIOVASCULAR DISEASES
Shaping the Future of Heart Disease ManagementPROGRESS IN CARDIOVASCULAR DISEASES is a leading journal in the field of cardiology and cardiovascular medicine, published by W B SAUNDERS CO-ELSEVIER INC. With an impressive impact factor that places it in the esteemed Q1 quartile of its category, this journal ranks among the top 32 out of 387 journals in its field, positioning itself in the 91st percentile. Since its inception in 1958 and continuing until 2024, it has been a prolific source of cutting-edge research, reviews, and clinical insights that contribute significantly to the understanding and treatment of cardiovascular diseases. Although it does not currently offer open access options, the journal's rigorous peer-review process ensures that all published content meets the highest standards of scientific excellence. As a key resource for researchers, practitioners, and students alike, PROGRESS IN CARDIOVASCULAR DISEASES serves as an indispensable tool for advancing knowledge and practice in cardiovascular health.